Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8858270 | 0.98 | KCNH2 (0.48) | KCNH2ALDH1A1PKMHPGDGPR84 | |
| SCHEMBL6889381 | 0.98 | KCNH2 (0.48) | KCNH2ALDH1A1PKMHPGDGPR84 | |
| SCHEMBL28376279 | 0.98 | KCNH2 (0.48) | KCNH2ALDH1A1PKMHPGDGPR84 | |
| SCHEMBL3842012 | 0.94 | HRH3 (0.41) | KCNH2ALDH1A1PKMHPGDHRH3 | |
| SCHEMBL1063754 | 0.90 | KCNH2 (0.47) | KCNH2ALDH1A1PKMHPGDGPR84 | |
| SCHEMBL10697416 | 0.89 | KCNH2 (0.50) | KCNH2ALDH1A1PKMHPGDGPR84 | |
| SCHEMBL4445935 | 0.89 | KCNH2 (0.50) | KCNH2ALDH1A1PKMHPGDGPR84 | |
| SCHEMBL9817100 | 0.89 | KCNH2 (0.50) | KCNH2ALDH1A1PKMHPGDGPR84 | |
| SCHEMBL730079 | 0.89 | KCNH2 (0.50) | KCNH2ALDH1A1PKMHPGDGPR84 | |
| SCHEMBL9133514 | 0.89 | KCNH2 (0.50) | KCNH2ALDH1A1PKMHPGDGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002003982-A1 | ANTIMYCOTIC PHARMACEUTICAL | INNOVATIONSAGENTUR GESELLSCHAFT M.B.H. (AT) | 2002-01-17 | — | — | WO | claimed |
| US-7625935-B2 | High purity butoconazole nitrate with specified particle size and a process for the preparation thereof | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-12-01 | — | — | US | disclosed |
| EP-1709005-B1 | HIGH PURITY BUTOCONAZOLE NITRATE WITH SPECIFIED PARTICLE SIZE AND A PROCESS FOR PREPARATION THEREOF | RICHTER GEDEON NYRT (HU) | 2009-07-15 | — | — | EP | disclosed |
| US-20080221190-A1 | High Purity Butoconazole Nitrate with Specified Particle Size and a Process for the Preparation Thereof | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-09-11 | — | — | US | disclosed |
| EP-1903035-A2 | High purity butoconazole nitrate with specified particle size and a process for preparation of thereof | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2008-03-26 | — | — | EP | disclosed |
| EP-1709005-A1 | HIGH PURITY BUTOCONAZOLE NITRATE WITH SPECIFIED PARTICLE SIZE AND A PROCESS FOR PREPARATION THEREOF | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070897-A1 | HIGH PURITY BUTOCONAZOLE NITRATE WITH SPECIFIED PARTICLE SIZE AND A PROCESS FOR PREPARATION THEREOF | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2005-08-04 | — | — | WO | disclosed |
| WO-2002003982-A1 | ANTIMYCOTIC PHARMACEUTICAL | INNOVATIONSAGENTUR GESELLSCHAFT M.B.H. (AT) | 2002-01-17 | — | — | WO | disclosed |
| EP-0897395-A1 | POLYMERS CONTAINING $g(b)-HYDROXY ALKYL VINYL AMINE UNITS, PROCESS FOR THEIR PRODUCTION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1999-02-24 | — | — | EP | disclosed |
| WO-1997042229-A1 | POLYMERS CONTAINING β-HYDROXY ALKYL VINYL AMINE UNITS, PROCESS FOR THEIR PRODUCTION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221190-A1 | High Purity Butoconazole Nitrate with Specified Particle Size and a Process for the Preparation Thereof | CYP1B1, CYP51A1, CYP3A5 | KCNH2 1477/4885ALDH1A1 430/4885PKM 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.